One of the first lessons CNS clinical trial management teaches you is that what works on paper does not always work in practice.
A protocol may be scientifically sound but difficult for sites to execute consistently. Introducing a technology intended to simplify study conduct may create additional burden for patients, caregivers, or site staff. A patient population that appears accessible during feasibility may prove more difficult to engage once recruitment begins.
As studies move from planning to execution, the gap between how a study was designed and how it actually runs often becomes clearer and wider. Successful study execution is not defined by the absence of these challenges, but by how effectively they are anticipated, interpreted, and addressed.
THE 20 YEAR DIFFERENCE
Two decades of exclusive CNS focus reshapes how teams approach risk, site collaboration, patient populations, and decision making.
As Tom Hochadel, Pharm.D., President of CRC, notes, protocols have become increasingly more challenging due to the number of outcomes and vendors involved in a clinical trial. As operational demands increase, teams develop a more informed view of the tradeoffs involved in study execution, where flexibility exists, where it doesn’t, and how similar challenges have been successfully addressed in the past.
Longstanding relationships with investigators and site staff, paired with years of experience across specific indications and patient populations, contribute to that understanding.
The examples that follow illustrate how experience influences decisions, relationships, and operational approaches that shape successful CNS study execution.
ENHANCED RISK DETECTION IN CNS CLINICAL TRIALS
In CNS, problems rarely announce themselves clearly. They appear as subtle patterns, inconsistencies, or faint signals that require context to interpret.
In a migraine study CRC supported, one of our CRAs identified irregularities at a site, not because of a checklist failure, but because the data and behavior didn’t align with what should be expected under the specific circumstances in that indication.
The CRC team immediately escalated the concern with the Program Manager, Quality Assurance and the sponsor was notified. The concern was validated and the site was discontinued from the study. Without that level of therapeutic familiarity, the issue may have gone undetected until much later, putting the study at risk.
Experienced CRA teams do not simply execute visits and document activity. At CRC, they take an active role in evaluating risk, identifying issues before they appear in reports, and stabilizing studies behind the scenes. As Sia Mayorga, Director of Clinical Operations, put it, “When CRAs understand the science and nuance behind CNS clinical trials, potential problems can be identified and addressed before they create broader study risks.”
This is especially critical in neuroscience research, where factors such as rater variability, inconsistent patient reporting, or subtle site behaviors can materially impact data quality.
CNS SITE SELECTION STRATEGY BEYOND A DATABASE
In neuroscience, site selection should not be solely database driven. Accumulated knowledge from longstanding relationships with investigators and site teams provides important insight into a site’s ability to meet enrollment goals, execute protocol requirements effectively, and maintain the level of engagement and responsiveness needed throughout the trial.
Together, these relationships and experiences often enable:
- More protocol specific site selection
- Quicker feasibility and study design insight
- More reliable enrollment projections and timelines
- Faster study startup timelines
- Better alignment between protocol requirements and site capability
- More consistent site performance throughout study execution
“It also opens the door to considerations that might otherwise be overlooked, such as engaging highly qualified physicians who may not have extensive research experience but are the right fit clinically for the patient population,” says Tom Hochadel, Pharm.D. These decisions don’t come from theory; they come from decades of direct experience.
PRACTICAL CNS PATIENT RECRUITMENT AND RETENTION STRATEGIES
In CNS, the conditions involved with a study can work against a patient’s ability or willingness to enroll and stay, which makes recruitment and retention less a matter of process than of understanding the population. As Eva Kemper, Associate VP of Clinical Operations, explains, success often comes down to understanding “the nuances behind recruiting the subjects and keeping them.”
Years of working closely with the same patient groups show where those nuances live:
- Patients who struggle to attend visits consistently
- Study requirements that do not fit how people manage daily life
- Retention that turns on small, practical accommodation rather than broad strategies
That kind of pattern recognition informs operational strategies tailored to the patient population and the objectives of the study. For example, when dropout concern increased in a large OCD study, the CRC team recognized that the challenge was rooted in how that patient population engaged with clinical environments. Working closely with sites, the team implemented practical accommodations that made participation more manageable. As site processes evolved to better reflect OCD patient needs, engagement and retention improved.
When teams understand those realities early, recruitment and retention stop being reactive problems and become part of how the study is operationalized from the start.
CNS CLINICAL TRIAL MANAGEMENT BEYOND EXECUTION
One of the most valuable outcomes of longstanding experience is knowing when a different approach may lead to a better outcome. Strong CNS clinical trial management teams don’t just execute; they evaluate, question, and advise.
That can mean:
- Challenging protocol complexities that may increase site or participant burden without meaningfully advancing study objectives
- Advising against certain sites, enrollment assumptions, or timelines when the associated risks outweigh the potential benefits
- Recommending simpler approaches or additional tools that have demonstrated value in similar studies and patient populations
It also requires strong sponsor partnerships, where guidance is delivered collaboratively rather than authoritatively, and recommendations are grounded in a clear understanding of sponsor objectives. As Brandy Isaacks, VP of Client Solutions, explains, “The goal is not simply to complete deliverables, but to ensure our clients’ studies produce meaningful and interpretable data to support their next steps.”
Many challenges in CNS clinical research are preventable when considered early enough to inform planning and key study decisions.
SELECTING THE RIGHT CRO
FOR CNS CLINICAL TRIAL MANAGEMENT
When sponsors evaluate CROs, clinical trial management capabilities often look similar on paper. The real differences tend to surface during study execution. If you’re assessing a partner for a CNS program, ask questions that go beyond structure and into operational judgement, experience, and approach.
HOW DO YOU EVALUATE AND SELECT CNS SITES, AND WHAT DO YOU KNOW ABOUT THEIR ACTUAL PERFORMANCE?
Look for answers grounded in experience, relationships, and indication-specific knowledge, not just feasibility data. The most meaningful answers will reflect long-standing relationships and direct experience. In CNS, knowing how a site behaves operationally is often more predictive than what they report upfront.
HOW DOES YOUR TEAM ENSURE CONSISTENCY IN CNS ASSESSMENTS AND DATA QUALITY ACROSS SITES?
Strong answers should address how rater variability is identified and managed, what monitoring approaches are used, and what signals trigger intervention before data quality is affected. The best teams don’t rely solely on dashboards; they combine data review with therapeutic understanding and active oversight.
WHAT HAVE YOU LEARNED ABOUT THIS PATIENT POPULATION THAT HAS CHANGED HOW YOU RUN STUDIES?
This question should reveal whether the CRO has operationalized real-world experience with CNS patients or is relying on general assumptions. Listen for specificity in responses. Answers should reflect real lessons learned and applied.
TELL ME ABOUT A TIME YOU RECOMMENDED AGAINST A SPONSOR’S APPROACH. WHAT HAPPENED?
The best partners don’t just execute. They bring perspective and use it to protect study outcomes. Strong partners should describe the situation, how they identified risk, how they communicated that perspective to the sponsor and the result. The goal is to understand whether the CRO brings informed perspective and the confidence to use it, especially when it matters most.
Sponsors deserve more than a CRO that can execute a protocol; they deserve a partner that cares about the outcome, brings the experience to guide critical decisions, and has the accountability to see the study through.
If clinical trial management is where complexity surfaces, it’s also where experience matters most – especially in CNS, where there is little margin for misalignment between plan and practice. After two decades dedicated exclusively to neuroscience, CRC has seen firsthand how experience shapes study execution, informs better decisions, and helps teams anticipate challenges before they affect outcomes.
